Nature Search

Erratum: Crystal structure of trp represser/operator complex at atomic resolution

Z. Otwinowski
R. W. Schevitz
P. B. Sigler
Amendments and Corrections27 Oct 1988
Nature

Volume: 335, P: 837
Root microbiota drive direct integration of phosphate stress and immunity

In Arabidopsis thaliana, a genetic network that controls the phosphate stress response also influences the structure of the root microbiome community, even under non-stress phosphate conditions.

Gabriel Castrillo
Paulo José Pereira Lima Teixeira
Jeffery L. Dangl
Research15 Mar 2017
Nature

Volume: 543, P: 513-518
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion

L Paz-Ares
R Kunka
P O'Dwyer
Research01 Nov 1998
British Journal of Cancer

Volume: 78, P: 1329-1336
Fear of flying

ROBERT L. PARKER
Research29 Dec 1988
Nature

Volume: 336, P: 719
Genome expansion of Arabis alpina linked with retrotransposition and reduced symmetric DNA methylation

Closely related plant species can have drastically different abundances of transposable elements. Now it is shown that the genome of Arabis alpina has experienced a striking expansion of retrotransposons, probably shaped by reduced DNA methylation.

Eva-Maria Willing
Vimal Rawat
Korbinian Schneeberger
Research02 Feb 2015
Nature Plants

Volume: 1, P: 1-7
Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma

Adèle L’Hostis
Jean-Louis Palgen
Claudio Monteiro
ResearchOpen Access31 Jul 2023
npj Systems Biology and Applications

Volume: 9, P: 1-13
Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state

Tumor-secreted midkine modulates immune tolerance in the melanoma tumor microenvironment and determines resistance to immune checkpoint blockade.

Daniela Cerezo-Wallis
Marta Contreras-Alcalde
María S. Soengas
Research19 Oct 2020
Nature Medicine

Volume: 26, P: 1865-1877
Molecular determinants of sotorasib clinical efficacy in KRAS^G12C-mutated non-small-cell lung cancer

This large integrated analysis of the KRAS^G12C inhibitor sotorasib clinical efficacy biomarkers from the phase 2 CodeBreaK 100 and phase 3 CodeBreaK 200 trials shows that low expression of TTF-1 and high expression of NRF2 determine anti-tumor efficacy of sotorasib in non–small-cell lung cancer.

Ferdinandos Skoulidis
Bob T. Li
Martin Schuler
ResearchOpen Access28 May 2025
Nature Medicine

Volume: 31, P: 2755-2767
Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells

A Olivieri
L Corvatta
P Leoni
Research14 May 1998
Bone Marrow Transplantation

Volume: 21, P: 1049-1053
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

In an arm of a phase 1b trial, the combination of divarasib, a KRAS G12C inhibitor, and cetuximab, an epidermal growth factor receptor inhibitor, was well tolerated with an encouraging overall response rate of 62.5% in patients with KRAS G12C-positive colorectal cancer.

Jayesh Desai
Guzman Alonso
Sae-Won Han
ResearchOpen Access05 Dec 2023
Nature Medicine

Volume: 30, P: 271-278
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Results from the precision oncology ARROW trial identify the RET receptor tyrosine kinase as a tissue-agnostic target and the drug pralsetinib’s potential as a well-tolerated treatment option with rapid, robust and durable anti-tumor activity in patients with diverse RET fusion–positive solid tumors.

Vivek Subbiah
Philippe A. Cassier
Giuseppe Curigliano
ResearchOpen Access12 Aug 2022
Nature Medicine

Volume: 28, P: 1640-1645
Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma

A first-in-class engineered receptor decoy that neutralizes CLCF1–CNTFR signaling exhibits antitumor activity in preclinical models of lung adenocarcinoma driven by some mutant KRAS variants and other oncogenic genotypes.

Jun W. Kim
Cesar P. Marquez
E. Alejandro Sweet-Cordero
Research07 Nov 2019
Nature Medicine

Volume: 25, P: 1783-1795
Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10–17)

Y J Choi
S H Lee
H Ahn
ResearchOpen Access27 Nov 2014
British Journal of Cancer

Volume: 112, P: 260-265
Low phosphate activates STOP1-ALMT1 to rapidly inhibit root cell elongation

Low Pi availability inhibits primary root growth, but the sensory mechanisms are not known. Here the authors uncover a signalling pathway regulating Pi-mediated root growth inhibition inArabidopsis, involving the transcription factor STOP1, its direct target ALMT1, a malate channel, and ferroxidase LPR1.

Coline Balzergue
Thibault Dartevelle
Thierry Desnos
ResearchOpen Access15 May 2017
Nature Communications

Volume: 8, P: 1-16
The JAZ family of repressors is the missing link in jasmonate signalling

JASMONATE-INSENSITIVE 3 (JAI3) and a family of related proteins named JAZ (jasmonate-ZIM-domain) are identified. JAI3 and some of the other JAZ proteins interact with the SCF^COI1 ubiquitin ligase complex. Additionally JAI3 and JAZ1 interact with AtMyc2, a key transcriptional activator of jasmonate-regulated gene expression.

A. Chini
S. Fonseca
R. Solano
Research18 Jul 2007
Nature

Volume: 448, P: 666-671
microRNA regulation of fruit growth

The mechanism of how plant growth is controlled during the reproductive phase is not well understood. Now a study reveals a new miRNA-dependent module integrating auxin signalling and developmental pathways to promote Arabidopsis fruit morphogenesis.

Juan José Ripoll
Lindsay J. Bailey
Martin F. Yanofsky
Research30 Mar 2015
Nature Plants

Volume: 1, P: 1-9
Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology

Irene Carretero-Barrio
Lara Pijuan
José Palacios
ResearchOpen Access15 Oct 2024
Scientific Reports

Volume: 14, P: 1-11
Autologous transplantation of mobilized peripheral blood CD34⁺ cells selected by immunomagnetic procedures in patients with multiple myeloma

R Abonour
KM Scott
K Cornetta
Research20 Nov 1998
Bone Marrow Transplantation

Volume: 22, P: 957-963
Melphalan 220 mg/m² followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma

P Moreau
N Milpied
J-L Harousseau
Research25 May 1999
Bone Marrow Transplantation

Volume: 23, P: 1003-1006
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

Transcriptional profiling of Kras-driven early lesions—aimed at identifying founder events—reveals DDR1 as a therapeutic target relevant to adenocarcinoma.

Chiara Ambrogio
Gonzalo Gómez-López
Mariano Barbacid
Research08 Feb 2016
Nature Medicine

Volume: 22, P: 270-277
Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma

R Colomer
J Aparicio
H Cortés-Funes
Research01 Nov 1997
British Journal of Cancer

Volume: 76, P: 1215-1220
Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine

E Erba
L Bassano
M D'Incalci
ResearchOpen Access07 May 2002
British Journal of Cancer

Volume: 86, P: 1510-1517
Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

M. Morfouace
S. Novello
B. Besse
ResearchOpen Access18 May 2022
Scientific Reports

Volume: 12, P: 1-11
Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

A L Cesne
I Judson
J-Y Blay
ResearchOpen Access10 Sept 2013
British Journal of Cancer

Volume: 109, P: 1717-1724
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium

Filipe Correia Martins
Dominique-Laurent Couturier
James D. Brenton
ResearchOpen Access18 Jun 2020
British Journal of Cancer

Volume: 123, P: 793-802
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

X García del Muro
E Marcuello
J R Germá
ResearchOpen Access11 Feb 2002
British Journal of Cancer

Volume: 86, P: 326-330
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

Ashley Weir
Eun-Young Kang
Susan J. Ramus
ResearchOpen Access02 Nov 2022
British Journal of Cancer

Volume: 128, P: 137-147
Retraction Note: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

A Gualberto
M L Hixon
M N Pollak
Amendments and CorrectionsOpen Access04 Dec 2012
British Journal of Cancer

Volume: 107, P: 2024
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

L Paz-Ares
H Ross
P Bonomi
ResearchOpen Access13 May 2008
British Journal of Cancer

Volume: 98, P: 1608-1613
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

T A Yap
H Cortes-Funes
J A López-Martin
ResearchOpen Access10 Apr 2012
British Journal of Cancer

Volume: 106, P: 1379-1385
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

A Gualberto
M L Hixon
M N Pollak
ResearchOpen Access23 Nov 2010
British Journal of Cancer

Volume: 104, P: 68-74
IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer

I Ibanez de Caceres
M Cortes-Sempere
R Perona
Research21 Dec 2009
Oncogene

Volume: 29, P: 1681-1690

Search

Erratum: Crystal structure of trp represser/operator complex at atomic resolution

Root microbiota drive direct integration of phosphate stress and immunity

A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion

Fear of flying

Genome expansion of Arabis alpina linked with retrotransposition and reduced symmetric DNA methylation

Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma

Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state

Molecular determinants of sotorasib clinical efficacy in KRAS^G12C-mutated non-small-cell lung cancer

Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma

Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10–17)

Low phosphate activates STOP1-ALMT1 to rapidly inhibit root cell elongation

The JAZ family of repressors is the missing link in jasmonate signalling

microRNA regulation of fruit growth

Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology

Autologous transplantation of mobilized peripheral blood CD34⁺ cells selected by immunomagnetic procedures in patients with multiple myeloma

Melphalan 220 mg/m² followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma

Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

Retraction Note: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer

Search

Quick links

Search

Filter By:

Search

Quick links